ALLO: Allogene Therapeutics, Inc. Stock

by  •  • Comments Off on ALLO: Allogene Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 349.10
Enterprise Value ($M) 297.87
Book Value ($M) 463.75
Book Value / Share 2.21
Price / Book 0.75
NCAV ($M) 179.04
NCAV / Share 0.85
Price / NCAV 1.95

Profitability (mra)
Return on Invested Capital (ROIC) -0.51
Return on Assets (ROA) -0.44
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 9.35
Current Ratio 9.35

Balance Sheet (mrq) ($M)
Current Assets 304.42
Assets 589.12
Liabilities 125.37
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-12 13G/A Vanguard Group Inc 3.98 0.00
11-08 13G/A BlackRock, Inc. 8.50 0.00
02-14 13G/A Belldegrun Arie 5.80 11.71
02-14 13G/A Chang David D 5.80 18.23
02-09 13G/A Fmr Llc 15.00 1.30
2024-01-23 13G/A State Street Corp 1.44 -73.52

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REP
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT P
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT
2024-03-14 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A _______________(Amendment No. 1)__________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal ye
2024-03-14 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 962,448 2,758,289 34.89
2025-02-03 1,896,895 4,308,927 44.02
2025-01-31 1,027,614 2,349,920 43.73
2025-01-30 953,719 3,456,608 27.59

(click for more detail)

Similar Companies
ALEC – Alector, Inc. ALKS – Alkermes plc
ALLK – Allakos Inc. ALNY – Alnylam Pharmaceuticals, Inc.
ALXO – ALX Oncology Holdings Inc.


Financial data and stock pages provided by
Fintel.io